Skip to content
DataLookout
Menu

NCT03270059

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Sep 15, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 15 versions: 9 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Final enrollment: 41 participants (planned 150)
  2. Notable Primary completion date: Aug 15, 2026 to Dec 15, 2027
    • Study completion date: Aug 15, 2027 to Dec 15, 2028
    • Site contact updated
    v14
  3. Notable Primary completion date: Aug 15, 2025 to Aug 15, 2026
    • Study completion date: Aug 15, 2026 to Aug 15, 2027
    v13
  4. Notable Primary completion date: Aug 15, 2023 to Aug 15, 2025
    • Study completion date: Aug 15, 2024 to Aug 15, 2026
    v10
  5. Notable Primary completion date: Aug 15, 2022 to Aug 15, 2023v9 Show 4 more changesShow less
    • Eligibility criteria shortened, about 15 words
    • Study completion date: Aug 15, 2023 to Aug 15, 2024
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description shortened, about 12 words
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Site contact updatedv8
  2. Notable Eligibility criteria expanded, about 25 words
    • Primary endpoints: 6 to 4
    • Study description expanded, about 21 words
    • Site contact updated
    v6
  3. Notable Eligibility criteria expanded, about 12 words
    • Primary endpoints: 4 to 6
    • Secondary endpoints reordered
    • Collaborators: 1 to 2
    v5
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 15, 2017 to Oct 6, 2017
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Visualization of normal vasculature
Timeframe: Up to 5 years
Visualization of abnormal vasculature
Timeframe: Up to 5 years
Visualization of normal anatomical structures
Timeframe: Up to 5 years
Identification of the lesion corresponding areas on cerebral blood volume (CBV) maps
Timeframe: Up to 5 years

Secondary (3)

Contrast enhancement
Border delineation
Internal morphology

Arms and interventions

Group I (gadolinium, ferumoxytol, MRI)Experimental

Patients receive gadolinium IV and then ferumoxytol IV and undergo MRI over 60 minutes on day 1.

Group II (ferumoxytol, gadolinium, MRI)Experimental

Patients receive ferumoxytol IV and then gadolinium IV and undergo MRI over 60 minutes on day 1.

Drugs: Ferumoxytol, Gadolinium

Procedures: Magnetic Resonance Imaging

Sites

1 site in 1 country

  • OHSU Knight Cancer InstitutePortland, Oregon, United States